Laurent ARNOULD
机构: Département de Pathologie CGFL DIJON
每年引用次数
引用次数
引用: 12,146
H-指数: 53
I10-指数 : 149
出版物: 455
Manifestation of porphyria cutanea tarda with cyproterone acetate
S. Dalac , J.-M. Petit , L. Arnoud , A.-F. Didier
European Journal of Dermatology 6 ( 7) 525 -526
1996
Chimiothérapie néoadjuvante FEC-HD dans le cancer du sein localement évolué
Arianne Darut-Jouve , Geneviève Jolimoy , Bruno Coudert , Jacques Guerrin
Bulletin Du Cancer 86 ( 2) 189 -194
1999
Neoadjuvant chemotherapy FEC-HD in localy advanced breast cancer
Arianne Darut-Jouve , Bruno Coudert , Geneviève Jolimoy , Catherine Belichard
Bulletin du Cancer 86 ( 2) 189 -94
5
1999
Implication of the Epstein-Barr virus in the progression of chronic lymphocytic leukaemia/small lymphocytic lymphoma to Hodgkin-like lymphomas.
G Rifle , P Fargeot , F Morlevat , O Depret
Anticancer Research 17 3907 -3913
41
1997
Le cancer du sein en adjuvant : quelles caractéristiques cliniques et histopathologiques en 2007?
L Arnould , F Penault-Llorca
Bulletin Du Cancer 97 ( 12) 1421 -1426
11
2010
Dermoid cyst of the ovary. False positive diagnosis in iodine 131 scintigraphy of differentiated thyroid cancers
G Vaillant , M Toubeau , J M Brun , S Rudoni
Presse Medicale 27 ( 27) 1379 -1381
8
1998
[Standards, options and recommendations for the composition of anatomic and surgical pathology reports or cytopathology reports in oncology].
L Arnould , M Fiche , MP Blanc-Vincent , V Le Doussal
Annales De Pathologie 23 ( 1) 79 -95
5
2003
Ganglioneuroblastoma in the adult
J P Favre , M Manuelian , Ph Rousseau , A Bernard
Presse Medicale 27 ( 33) 1677 -1679
5
1998
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival
S Ladoire , L Arnould , G Mignot , L Apetoh
British Journal of Cancer 105 ( 3) 366 -371
51
2011
Abstract P4-08-23: EndoPredict prognostic signature in pN1mi, estrogen receptor-positive breast cancer: analysis of the French national registry for molecular signatures
M LaCroix-Triki , L Arnould , G MacGrogan , F Penault-Llorca
Cancer Research 79
2019
Abstract P4-15-02: TILs variations, proliferative response and PEPI scores in patients with luminal breast cancer receiving neoadjuvant letrozole-palbociclib or chemotherapy: An extended analysis of the NEOPAL trial
A Vincent-Salomon , M-C Mathieu , G Bataillon , L Arnould
Cancer Research 79
2019
Abstract P5-12-05: Phenotypic discordance between primary and metastatic breast cancer (MBC) in a large scale real-life multicentre French cohort
S Lefevre , A Lusque , N Joyon , L Arnould
Cancer Research 79
2019
Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions.
G MacGrogan , L Arnould , I de Mascarel , A Vincent-Salomon
Histopathology 52 ( 6) 689 -697
19
2008
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.
A Vincent-Salomon , G MacGrogan , J Couturier , L Arnould
Histopathology 42 ( 4) 337 -347
107
2003
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
S Guiu , M Gauthier , B Coudert , F Bonnetain
British Journal of Cancer 103 ( 9) 1335 -1342
32
2010
Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.
Frédérique Végran , Romain Boidot , Bruno Coudert , Pierre Fumoleau
British Journal of Cancer 101 ( 8) 1357 -1364
31
2009
Abstract P1-11-02: Pathologic Response and Survival after Neoadjuvant Therapy for Breast Cancer: A 30-Year Single-Center Study
S Guiu , L Arnould , M Gauthier , L Favier
Cancer Research 70
2010
Abstract P5-01-09: Evaluation of Tumor Blood Flow with Dynamic18F-Fluorodeoxyglucose Positron Emission Tomography: Correlation with Microvessel Density
A Cochet , S Pigeonnat , B Buvry , A Berriolo-Riedinger
Cancer Research 70
2010
Abstract PD07-05: In Situ Immune Response after Neoadjuvant Chemotherapy for Breast Cancer Predicts Survival
S Ladoire , B Coudert , P Fumoleau , L Arnould
Cancer Research 70
2010
Carcinome canalaire in situ : est-il éthique de considérer le traitement conservateur comme un standard ?
I Barillot , B Cutuli , L Arnould
Cancer Radiotherapie 8 ( 1) 9 -20
4
2004
Bruno Coudert frederique Penault-llorca Sylvain Ladoire Pierre Fumoleau Boidot Romain Charles COUTANT François BRUNOTTE fabrice andre Olivier Humbert Suzette Delaloge ROUZIER Roman Frederique Vegran Paul Cottu Carole Mathelin Jean-Pierre Ghnassia Gilles Paintaud bonnotte bernard Laurence Zitvogel mario campone